Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans

Toxicology Letters

Volumn 120, Issue 1-3, 2001, Pages 9-19

  Bar Tana, Jacob ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Atherosclerosis; Differentiation; Insulin resistance; PPAR ; Thiazolidinediones

Indexed keywords

CYTOKINE; ICOSANOID; INSULIN; MUTANT PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYUNSATURATED FATTY ACID; THIAZOLIDINE DERIVATIVE;

ATHEROGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; CONFERENCE PAPER; FOAM CELL; GENE ACTIVATION; HUMAN; INSULIN SENSITIVITY; PRIORITY JOURNAL; RECEPTOR BINDING; TARGET ORGAN; TISSUE SPECIFICITY; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CELL DIFFERENTIATION; CYTOKINES; FOAM CELLS; HUMANS; INSULIN; MUSCLE, SMOOTH, VASCULAR; ORGAN SPECIFICITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035977861     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00302-2     Document Type: Conference Paper

References (70)

1. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
2. Efficacy of troglitazone on body fat distribution in type 2 diabetes
3. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
4. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
5. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
6. An anti-diabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues
7. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
8. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat
9. Troglitazone action is independent of adipose tissue
10. 2
11. 2 in activated murine macrophages
12. Peroxisome proliferator-activated receptor (PPAR) γ: Adipose-predominant expression and induction early in adipocyte differentiation
13. PPAR γ agonists enhance human vascular endothelial adhesiveness by increasing ICAM-1 expression
14. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity
15. 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
16. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma
17. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
18. A new thiazolidinedione, NC-2100, which is a weak PPARγ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice
19. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
20. PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells
21. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes
22. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
23. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR γ and C/EBPα
24. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
25. Peroxisome proliferator, activated receptor-γ ligands inhibit nitric oxide synthesis in vascular smooth muscle cells
26. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
27. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
28. PPARγ agonists inhibit production of monocyte inflammatory cytokines
29. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
30. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus
31. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells
32. Skeletal muscle peroxisome proliferator-activated receptor-γ expression in obesity and non- insulin-dependent diabetes mellitus
33. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
34. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
35. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
36. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
37. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
38. Atherosclerosis
39. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease
40. 2 on thiazolidinedione-induced adipogenesis
41. Improved insulin-sensitivity in mice heterozygous for PPARγ deficiency
42. Effect of troglitazone on body fat distribution in type 2 diabetic patients
43. Terminal differentiation of human breast cancer through PPARγ
44. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer
45. 1 and activation with retinoid X receptor agonists and antagonists
46. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
47. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse
48. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells
49. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
50. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators
51. Transcriptional control of adipogenesis
52. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties
53. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
54. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
55. The pathogenesis of atherosclerosis: A perspective for the 1990s
56. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
57. Differentiation and reversal of malignant changes in colon cancer through PPARγ
58. Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1β cytotoxicity
59. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice
60. Down-regulation by troglitazone of hepatic tumor necrosis factor-α and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes
61. PPARγ: Adipogenic regulator and thiazolidinedione receptor
62. A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response
63. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNFα responses of macrophages to lipopolysaccharide in vitro or in vivo
64. 2: Tissue-specific regulator of an adipocyte enhancer
65. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
66. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
67. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
68. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells
69. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones
70. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ